XERAGENX Trademark

Trademark Overview

On Friday, January 24, 2020, a trademark application was filed for XERAGENX with the United States Patent and Trademark Office. The USPTO has given the XERAGENX trademark a serial number of 88772811. The federal status of this trademark filing is REGISTERED as of Tuesday, October 13, 2020. This trademark is owned by Xeragenx Holdings LLC. The XERAGENX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development
xeragenx

General Information

Serial Number88772811
Word MarkXERAGENX
Filing DateFriday, January 24, 2020
Status700 - REGISTERED
Status DateTuesday, October 13, 2020
Registration Number6173315
Registration DateTuesday, October 13, 2020
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 28, 2020

Trademark Statements

Goods and ServicesPharmaceutical research and development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, January 29, 2020
Primary Code042
First Use Anywhere DateThursday, September 1, 2011
First Use In Commerce DateThursday, September 1, 2011

Trademark Owner History

Party NameXeragenx Holdings LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressAlpharetta, GA 30022
Party NameXeragenx Holdings LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressAlpharetta, GA 30022
Party NameXeragenx Holdings LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressAlpharetta, GA 30022

Trademark Events

Event DateEvent Description
Tuesday, April 14, 2020NON-FINAL ACTION WRITTEN
Tuesday, January 28, 2020NEW APPLICATION ENTERED
Wednesday, January 29, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 14, 2020ASSIGNED TO EXAMINER
Tuesday, April 14, 2020NON-FINAL ACTION E-MAILED
Tuesday, April 14, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 14, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 14, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 14, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 15, 2020REPORT UNRESPONSIVE AMENDMENT - COMPLETED
Wednesday, April 15, 2020NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
Wednesday, April 15, 2020NOTIFICATION OF NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
Saturday, June 6, 2020FINAL REFUSAL E-MAILED
Friday, June 5, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 5, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, June 6, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 5, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, June 6, 2020FINAL REFUSAL WRITTEN
Saturday, June 6, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, June 8, 2020TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, June 22, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 8, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 28, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 13, 2020REGISTERED-PRINCIPAL REGISTER
Monday, October 13, 2025COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, July 28, 2020PUBLISHED FOR OPPOSITION
Monday, June 8, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 9, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 18, 2020ASSIGNED TO LIE

Related Keywords

xeragenx development research pharmaceutical